Neurology
Expert perspectives on neurological conditions, stroke management, movement disorders, and neuromuscular disease.
Recent Discussions
Does anyone utilize P2Y12 assays to determine if clopidogrel may be ineffective when used for DAPT?
Yes, I use P2Y12 assays in two distinct settings. Medical management: If a patient on clopidogrel mono/dual therapy has disease progression with ICAD or experiences a recurrent ischemic event, I obtain a P2Y12 assay to assess responsiveness. This helps guide the decision to switch to ticagrelor and ...
How do you approach treatment of a glioblastoma in pregnancy?
Glioblastoma during pregnancy could be treated safely (to mother and fetus) with certain precautions and modifications. Collaboration and consultation with the patient’s obstetrician are essential. External shielding over the patient’s abdomen during treatment will decrease the external scatter radi...
How do you assess the risk of developing demyelinating disease when initiating TNF inhibitors?
First, a bit of history. In the 1990s, TNFi were studied as potential drugs to treat multiple sclerosis (MS). One product in particular, lenercept a soluble p55 TNF receptor IgG fusion protein, showed promise in animal models of MS. However, in phase II trials studying its role as a treatment for MS...
In a young patient with recurrent low-grade glioma s/p gross total resection, is there any role for further observation instead of radiation and chemotherapy?
As simple as this question seems to be on the surface, it is actually a very difficult clinical scenario to opine with certainty, primarily because of a lack of data. So, let us address this with each option in mind, weighing the pros and cons: Observation: We do know that in resected patients, radi...
How do you manage daytime somnolence without a clear cause?
Throw a broad net out for the evaluation because we don't know how much has a physiological component and how much is mental/emotional. At intake, I get a moderately comprehensive set of labs. Rating Scales like HAMA, HAM-D, PHQ-9, Epworth Sleepiness Scale, and a ROS (Review of Systems) are done. I...
What is your approach to Tardive Dyskinesia when VMAT2 inhibitors are ineffective or unaffordable?
In established cases of tardive dyskinesia, in which withdrawal-emergent dyskinesia has been ruled out, and dyskinesia has persisted despite a sufficient washout interval after removal of the offending agent, VAM2 inhibitors such as valbenazine and deutetrabenazine are used for pharmacotherapy. If t...
What is your preferred first-line agent to treat anxiety in patients with Parkinson's disease?
Any standard SSRI/SNRI can be tried. I like to try the SNRIs duloxetine or venlafaxine. If comorbid insomnia is a problem, mirtazapine may be a good choice. Think about talk therapy too. It is important to make sure episodic anxiety is not a non-motor symptom fluctuation related to levodopa or oth...
When do you repeat HSV CSF PCR testing for suspected encephalitis if the initial result is negative and was sent within 72 hours of symptoms?
If suspicion is high enough (such as typical prodromal symptoms, typical MRI findings, or the presence of LPDs on EEG), I would continue acyclovir and repeat the lumbar puncture in 3-5 days from the original one. HSV PCR on CSF typically remains positive for the first 10-14 days of treatment.
What is your management approach to a patient who develops a CVST while on a DOAC?
This is an excellent question. First and foremost, it is important to understand the underlying etiology of cerebral venous sinus thrombosis (CVST) occurring despite ongoing direct oral anticoagulant (DOAC) therapy. For instance, is the event driven by an acquired prothrombotic condition, such as ma...
Would you consider giving platelet transfusion in a patient with spontaneous intracerebral hemorrhage who is on an irreversible antiplatelet agent such as prasugrel?
This question seems logical, but in fact, there has been a clinical trial, the PATCH trial, that found no benefit of platelet transfusion; in fact, both deaths and poor outcomes were more prevalent in the platelet transfusion group than in the control group.